According to Opiant Pharmaceuticals, the US Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $3.5 million for development of Opiant's OPNT003 nalmefene nasal spray for the treatment of opioid overdose. BARDA had previously provided $4.6 million. The company has also received funding from the National Institute on Drug … [Read more...] about Opiant gets additional $3.5 million from BARDA for development of intranasal nalmefene
Business
UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development of a once-daily nasal spray for the prevention of viral infections through a Phase 1 study. Researchers say that because they already … [Read more...] about UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
Cyrano raises almost $13 million for Phase 2 trial of intranasal theophylline to restore sense of smell
Cyrano Therapeutics announced that it has raised $12.8 million in Series A financing to allow it to complete a Phase 2 trial of its CYR-064 intranasal theophylline for the restoration of the senses of smell and taste. In October 2017, Cyrano announced that it had partnered with Shanghai Newsummit Biopharma for development of the nasal spray in China; the new funding … [Read more...] about Cyrano raises almost $13 million for Phase 2 trial of intranasal theophylline to restore sense of smell
Savara halts development of AeroVanc, Apulmiq
Savara Pharmaceuticals has announced that it is halting development of its AeroVanc vancomycin DPI after the Phase 3 AVAIL trial of AeroVanc for the treatment of MRSA lung infections in cystic fibrosis patients failed to meet its primary endpoint. The AVAIL trial, which was initiated in 2017, failed to show statistically significant improvement in lung function or a … [Read more...] about Savara halts development of AeroVanc, Apulmiq
Kindeva to develop inhaled cannabinoid formulations for BOL Pharma
Kindeva Drug Delivery has announced a new agreement with Israeli medical cannabis company Breath of Life International (BOL Pharma) for development of formulations of several cannabinoids for delivery via Kindeva MDIs. The formulations will initially be for the purpose of feasibility studies. BOL intends to develop the MDIs for the treatment of CND conditions … [Read more...] about Kindeva to develop inhaled cannabinoid formulations for BOL Pharma
Kinaset to develop Vectura inhaled pan-JAK inhibitor for the treatment of asthma
US-based startup Kinaset Therapeutics has signed a licensing and develop an inhaled pan-JAK inhibitor that was in Vectura's pipeline prior to that company's transformation into an inhalation CDMO. In July 2019, Vectura announced that it intended to find partners for development of its inhaled drug candidates. The pan-Jak inhibitor, called VR588 by Vectura and now … [Read more...] about Kinaset to develop Vectura inhaled pan-JAK inhibitor for the treatment of asthma
Dr. Reddy’s acquires several mometasone nasal sprays from Glenmark
Dr. Reddy’s Laboratories said that it has acquired several mometasone and mometasone/azelastine nasal sprays for the treatment of seasonal and perennial allergic rhinitis from Glenmark for Russia, Kazakhstan, Uzbekistan, and Ukraine. The brands included in the deal include Momat Rino (Russia, Kazakhstan, Uzbekistan); Momat Rino Advance (Russia), Momat A (Kazakhstan, … [Read more...] about Dr. Reddy’s acquires several mometasone nasal sprays from Glenmark
Verona Pharma gets up to $30 million in debt financing for pre-commercialization activities for nebulized ensifentrine
Verona Pharma announced that it has secured up to $30 million in debt financing facility from Silicon Valley Bank for pre-commercialization activities related to the company's nebulized ensifentrine, which is in Phase 3 development for the treatment of COPD. The credit line allows Verona to borrow $5 million at closing, then a further $10 million through mid-2022 if … [Read more...] about Verona Pharma gets up to $30 million in debt financing for pre-commercialization activities for nebulized ensifentrine
US Court of Appeals upholds judgment against GSK for infringing on Vectura patents
According to inhalation CDMO Vectura, the United States Court of Appeals for the Federal Circuit has upheld a ruling by the District Court of Delaware against GlaxoSmithKline for infringing on a Vectura patent and has denied GSK a new trial. If GSK wants to ask to have the case heard again, it has 30 days to file a petition. In May 2019, a jury found that GSK … [Read more...] about US Court of Appeals upholds judgment against GSK for infringing on Vectura patents
BlueWillow and Medigen partner on development of intranasal vaccine to prevent COVID-19
Medigen Vaccine Biologics and BlueWillow Biologics have partnered for development of S-2P-NE-01, an intranasal vaccine against the SARS-CoV-2 virus, the companies said. According to the announcement, the vaccine will include BlueWillow's NanoVax nasal vaccine adjuvant and Medigen's S-2P spike protein; preclinical studies in mice have shown that the combination … [Read more...] about BlueWillow and Medigen partner on development of intranasal vaccine to prevent COVID-19